The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

One of these suggested stocks features a dividend yield topping 10%.

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case ...

All three of these stocks sport dividend yields above 6%.

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.